National Cancer Institute

TitleOrganizationKeywordsActivity CodeFOALOI Due DateApplication Due Date
(NOSI): Administrative Supplements for NCI Global Oncology Mentored ResearchNational Cancer Institutehealth disparities, prevention, diagnosis, treatment, survivorship, Native American, Alaska NativeAdmin SuppNOT-CA-24-0285/15/2024
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)National Institutes of Healthclinical trials, early phase, treatment, diagnosis, innovative therapiesPAR-24-0851/5/20246/5/2024
(NOSI): Administrative Supplements for Assessing and Enhancing Survivorship CareNational Cancer Instituteearly career, survivorship, health care,admin supplementNOT-CA-24-0416/5/2024
The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)National Cancer InstituteCommunity oncology, Cancer prevention research, Career development, Clinical trials, early career K12PAR-24-1536/8/2024
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)National Cancer Institutecancer informatics, clinical trials (optional), technology development, data management, research toolsRFA-CA-24-0195/12/20246/11/2024
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)National Cancer Institutecancer informatics, clinical trials (optional), technology development, early adopters, innovationRFA-CA-24-0185/12/20246/11/2024
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)National Cancer Institutecancer informatics, clinical trials (optional), technology development, proof-of-concept, feasibilityRFA-CA-24-0175/12/20246/11/2024
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)National Cancer Institutecancer informatics, algorithms, machine learning, artificial intelligence, data analysis, modelingRFA-CA-24-0165/12/20246/11/2024
NCI Mentored Research Scientist Development Award (K01)National Cancer Instituteearly career development, independent research6/12/2024
NCI Mentored Research Scientist Development Award to Promote Diversity (K08 No Independent Clinical Trials)National Cancer Instituteearly-career, mentored, diversity, PAR-21-3006/12/2024
(NOSI): Administrative Supplement to Support the NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) ResearchNational Cancer Instituteadministrative supplement, NCI, Cancer Prevention, Interception, Targeted Agent Discovery Program, CAP-IT, researchAdmin SuppNOT-CA-24-0476/14/2024
(NOSI): Administrative Supplements for the Study of the Diverse Aspects of Uterine Serous Carcinoma (Clinical Trial Not Allowed)National Cancer Instituteadministrative supplement, uterine serous carcinoma, diverse aspects, study, NCI, National Cancer InstituteAdmin SuppNOT-CA-24-0447/1/2024
(NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer ImmunotherapyNational Cancer Instituteimmunotherapy, Basic mechanisms, irAEs R01,R21,K99/R00,K01,K08,K22,R03,R15NOT-CA-22-0637/4/2024
(NOSI): Administrative Supplements to Support Collection of Spanish Normative Data and Determination of Test-Retest Reliability Estimates of Neuropsychological Tests for NCI Clinical Trials?National Cancer Instituteadministrative supplement, Spanish normative data, test-retest reliability, neuropsychological tests, NCIAdmin SuppNOT-CA-24-0407/22/2024
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)?National Cancer Instituteearly career, predoctoral, diversityPA-23-2718/8/2024
Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)National Cancer Institutesmall business, transition grant, early career scientists, R41, R42, clinical trial not allowed, R41 / R42RFA-CA-24-0237/21/20248/21/2024
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)National Cancer InstituteSBIR, Phase IIB, bridge awards, cancer-relevant technologies, commercialization, R44, clinical trial optional, NCIR44RFA-CA-24-0227/21/20248/21/2024
(NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource SettingsNational Cancer Institutelow-resource settings, minorities, community, clinical trialsR43/R44,R41/R42NOT-CA-21-0629/6/2024
(NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and PreventionNational Cancer InstituteLow-resource settings, affordable, dietary effects, tumor development, nutritional strategies, oncometabolites, signaling pathways, gene regulation, cellular processes, cell fate decisions, metabolic homeostasis, stem cell changes, systemic or local inflammation, pro-tumorigenic environment, treatment-related cardiotoxicity, early detection, childhood cancer survivorsK22,K08,R15,R01,R21,K99/R00,NOT-CA-21-1219/7/2024
(NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal CancerNational Cancer InstituteEarly detection, disparities, diagnosis, underserved populations, underrepresented populationsK01,R01,K22,K08,R21,U34,K99/R00,P01,R34NOT-CA-23-0189/7/2024
(NOSI): Mechanisms Driving Obesity
and Prostate Cancer Risk
National Cancer Institutesurveillance methods, data collection, analysis, dissemination, trends, patterns, Early detection, emerging threats R01,K99/R00,R21,K08,K22NOT-CA-23-0899/7/2024
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)National Cancer InstituteHealth disparities U54RFA-CA-24-0208/26/20249/26/2024
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)National Cancer Institutebiospecimens, biobanking, tissue preservation, biomarkers, genomics, proteomics, precision medicineRFA-CA-24-0109/1/202410/1/2024
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)National Cancer Institutemolecular analysis, cellular analysis, diagnostics, therapeutics, drug development, precision medicine, nanotechnologyRFA-CA-24-0089/1/202410/1/2024
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)National Cancer Institutebiospecimen science, technology development, validation, biobanking, tissue preservation, biomarkers, precision medicineRFA-CA-24-0119/1/202410/1/2024
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)National Cancer Institutemolecular analysis, cellular analysis, technology development, validation, diagnostics, therapeutics, drug development, precision medicineRFA-CA-24-0099/1/202410/1/2024
(NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and TreatmentNational Cancer InstituteInterprofessional teamwork, Interventions, CollaborationR03,R01,R21,P01NOT-CA-22-01410/8/2024
(NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer SurvivorsNational Cancer InstituteDisparities, childhood cancer survivors, InterventionsR01,R21,P01,R03NOT-CA-22-02910/8/2024
(NOSI): Improving Outcomes in Cancer Treatment-Related CardiotoxicityNational Cancer Institutecardiotoxicity, heart health, collaboration, early detection, preventionR01,R03,R21,P01NOT-CA-22-00111/5/2024
(NOSI): Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer InstituteNational Cancer InstituteEarly-career, academic scientists, diagnostics, therapeutics, K22,K08,K99/R00,K01NOT-CA-23-03511/12/2024
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)National Cancer InstituteNCI, Predoctoral, Postdoctoral, training, Fellow Transition Award, Early StageRFA-CA-23-04211/19/2024
Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)National Cancer InstituteKaposi sarcoma herpesvirus, virus, vaccine, therapeutic, innovationRFA-CA-24-00611/4/202312/4/2024
(NOSI): Technologies and Informatics Tools for Cancer MetabolomicsNational Cancer InstituteInformatics, Metabolomics, Molecular Analysis, lipidomics, low-resourceR33,R61,R21,U24,U01NOT-CA-22-08312/30/2024
(NOSI): Technology Development for Cancer Control and Population Science ResearchNational Cancer InstituteMicrobiome, development, progression, therapeutic targetsU01,R21,R61,R33,U24NOT-CA-23-03712/30/2024
(NOSI): Adaptive Biomaterials for Cancer BiologyNational Cancer InstituteAdaptive biomaterials, Biology, biomaterials, diagnostic, therapeuticR01,K22,K99/R00NOT-CA-23-0305/6/2025
(NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical TrialsNational Cancer InstituteInnovative technologies, prevention, early detection, new technologies, Admin SuppNOT-CA-23-0716/30/2025
(NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of CancersNational Cancer InstituteEarly detection, Advanced biomarkers, High-risk individuals, early detectionR43/R44,R21,R01,UH2/UH3,R41/R42,U01NOT-CA-23-0047/1/2025
(NOSI): Pragmatic Trials in Low Resource SettingsNational Cancer Instituteclinical trials, Low-resource settings, interventions, routine healthcare, underserved populations, health disparitiesUG3/UH3NOT-CA-23-07811/17/2025
(NOSI): RNA Modifications in Cancer BiologyNational Cancer InstitutePrecision prevention, AI, high risk, prevention strategiesR33,R21,U01,R61,R03NOT-CA-23-0601/7/2026
(NOSI): Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Risk?National Cancer Institutedisparities, epidemiology, NOT-CA-24-0375/9/2026
(NOSI): Research on HIV-associated MalignanciesNational Cancer InstituteSocial, behavioral , communication, education, strategies, prevention, early detection, treatment, health disparities R21,R01NOT-CA-23-0709/7/2026
(NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe)National Cancer InstituteClinical decision support tools, CDSTs, care delivery, clinical decision-making, patient outcomesR21NOT-CA-24-01611/16/2026
(NOSI): National Cancer Institute Entrepreneurial Education Programs to Facilitate Commercialization of Cancer Relevant TechnologiesNational Cancer InstituteSocial determinants, health disparities, SDOH, evaluating interventionsR25NOT-CA-24-0011/7/2027
(NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in CancerNational Cancer InstituteCannabis, cannabinoids, interception, therapeutic applications, biologyK22,R01,K08,K01,R21,R03,K99/R00NOT-CA-22-0857/4/2027
(NOSI): Research Projects to Develop Oncoaging Models for Cancer ResearchNational Cancer InstituteEquity, equitable care, interventionsR21,R01NOT-CA-23-0927/30/2027
(NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Control and Population SciencesNational Cancer InstituteMentored Research, Development Awards, Population Sciences, susceptibility factors, genetic, epigenetic, immunological, inflammatory, hormonal, social, cultural, ethnic, Intervention development, obacco, alcohol, diet, physical activity, behavioral, psychosocialK01NOT-CA-24-0225/7/2029
(NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer PreventionNational Cancer InstituteMentored Research, Development Awards, Down syndromeK01NOT-CA-24-0235/7/2029

Can’t find what you’re looking for? Please contact researchdevelopment@cancer.ufl.edu for assistance in finding additional funding opportunities.

NCI Cancer Center badge